Elevated Blood Pressure
Rising systolic and diastolic pressure strain arteries and the heart over time.
Metabolic health is the quiet engine of your wellbeing. When it runs smoothly, energy is steady, mood is balanced, and your body uses fuel efficiently. But chronic stress, poor sleep, processed diets, and sedentary habits push the system out of balance, and the warning signs rarely stay in one place. They show up everywhere, long before they show up on the scale.
Rising systolic and diastolic pressure strain arteries and the heart over time.
Cells stop responding to insulin, pushing fasting glucose steadily higher.
Excess fat accumulates in liver cells, fueling inflammation and NAFLD.
Visceral fat releases inflammatory signals that disrupt the entire metabolic system.
Damaged LDL particles drive arterial plaque and cardiovascular strain.
Reduced oxygen utilization leaves you tired, foggy, and slow to recover.

Clinically shown to reduce systolic BP by 11.2% and diastolic by 12.2% in 6 weeks.Response starts <48 hrs.
Published research shows reduced LDL, oxidized LDL, hepatic fat, and liver fibrosis.
Boosts oxygen consumption, Mitochondrial biogenesis, ATP production, and HO-1 antioxidant activity.

A nonrandomized clinical trial conducted at Natural Medicine of Stillwater evaluated ThymoQuin® (500 mg/day, delivering 15 mg thymoquinone) in 20 adults over a 42-day treatment period. Daily blood pressure monitoring revealed significant reductions in both systolic and diastolic pressure, with initial effects measurable within just 48 hours of supplementation. After a washout and placebo crossover, blood pressure trended back toward baseline, confirming the effect was driven by ThymoQuin itself.
− 11.2%
Reduction from 143.5 to 127.3 mm Hg over 6 weeks of daily use.
− 12.2%
Reduction from 90.7 to 79.6 mm Hg over 6 weeks of daily use.
48 hrs
Significant BP decline measured within two days of dosing.
120 / 80
Average BP normalized from 140/90 in subjects off medication.

Statistically significant reduction in fasting glucose vs. high-fat controls.
Reduced liver fat, droplet diameter, and fibrosis, protecting against NAFLD.
Significant decrease in LDL and oxidized LDL, key drivers of metabolic risk.
Increased oxygen use, fusion proteins (Mfn1, Mfn2, OPA1), and HO-1 activity.
Not all black seed oils are created equal. Most products on the market contain less than 1% thymoquinone with high free fatty acid levels (rancidity), meaning lower potency, poor stability, and inconsistent results. Some competitors claim 5–10% TQ, but research shows this can actually harm the beneficial gut bacteria the ingredient is supposed to support.
| PARAMETER | ThymoQuin® | Generic BSO |
|---|---|---|
| Thymoquinone (TQ) | ≥3% (standardized) | <1% (variable) |
| p-Cymene | >1% (controlled) | Uncontrolled (variable) |
| Free Fatty Acids | ≤1.25% | 7–50% |
| USP Monograph | Meets all standards | Does not meet |
| Clinical Validation | Double-blind, placebo-controlled | No clinical trials |
Our team can help you understand how ThymoQuin fits into your metabolic health, cardiovascular, or lipid-support formulation, from clinical data to dosing guidance to regulatory support.
Metabolic health refers to how effectively the body regulates energy, blood sugar, lipids, blood pressure, and other processes involved in maintaining physiological balance
Cortisol is one of the body's main metabolic hormones. In short bursts, it mobilizes energy. When stress keeps it elevated, cortisol can affect appetite, energy regulation, sleep, and where the body tends to store energy. That's why stress and weight are so often discussed together.
This makes a healthy stress response a foundation for metabolic wellness. ThymoQuin® is clinically studied for stress and cortisol modulation: in a four-week clinical study, participants saw a 44% reduction in salivary cortisol within three weeks. ThymoQuin® is not a weight-loss ingredient. Its role is supporting the stress response that metabolic balance depends on.
ThymoQuin® is one standardized ingredient that has been clinically studied across several of these systems at a single 500 mg daily dose. Human research has evaluated cortisol, stress resilience, sleep quality, mood, and gut microbiome composition. These systems are connected: chronic stress disrupts the gut, and a disrupted gut amplifies the stress response. Supporting both arms of that loop supports the systems metabolic wellness relies on.
| Endpoint | Study type | Key finding |
|---|---|---|
| Cortisol | Human RCT, 500 mg/day, 4 weeks (Talbott 2022) | 44% reduction in salivary cortisol within three weeks |
| Gut microbiome | Same human RCT (Talbott 2022) | Higher beneficial bacteria and improved microbiome composition |
| Stress resilience & sleep | Human RCT, 8 weeks (Talbott 2026) | Improved stress resilience and sleep quality |
| Blood pressure | Human clinical trial, 6 weeks (Bush 2020) | Reductions in systolic and diastolic blood pressure |
| Metabolic markers | Preclinical, murine model (Licari 2019) | Changes in glucose, LDL, liver fat, and mitochondrial markers |
Preclinical findings show a possible mechanism. They are not human outcomes.
Blood sugar and lipids have not been primary endpoints in human clinical studies of ThymoQuin®. A preclinical study in a murine model of diet-induced obesity found changes in fasting glucose and LDL with ThymoQuin® (Licari 2019). That research points to a mechanism, but it doesn't establish human outcomes.
Formulators should not make blood sugar, cholesterol, or triglyceride claims based on ThymoQuin® at this time. ThymoQuin®'s substantiated story is the stress response and gut balance.
In preclinical research in a murine model, ThymoQuin® was associated with increased oxygen consumption and higher levels of mitochondrial biogenesis and fusion markers (PGC-1α, Mfn1, Mfn2, OPA1). There is no human data yet on mitochondrial function or ATP production. ThymoQuin® should be positioned as complementing established mitochondrial nutrients, not replacing them.
In preclinical research in a murine model, ThymoQuin® was associated with increased oxygen consumption and higher levels of mitochondrial biogenesis and fusion markers (PGC-1α, Mfn1, Mfn2, OPA1). There is no human data yet on mitochondrial function or ATP production. ThymoQuin® should be positioned as complementing established mitochondrial nutrients, not replacing them.
Full-spectrum means ThymoQuin® is the whole cold-pressed oil of the Nigella sativa seed, not an isolated compound. It keeps the seed's naturally occurring constituents in their natural ratios, the same form used in the clinical research. That's part of why a single ingredient has been studied across several connected systems: stress response, gut balance, sleep, and mood.
ThymoQuin®, supplied by TriNutra Ltd., is a patented, branded black seed oil ingredient with human clinical data on cortisol, sleep quality, stress resilience, mood, and gut microbiome composition, plus supporting preclinical metabolic research. Licensees get the clinical dossier, batch Certificates of Analysis, Eurofins NSF/ANSI 173 certification (Certificate 20260803-0001), and claims support.
In clinical research, changes in cortisol were observed within three weeks, while other outcomes were evaluated over longer study periods. Individual responses may vary.
No. ThymoQuin® is cold-pressed, full-spectrum, standardized to at least 3% thymoquinone, and verified in every batch. It also features:
Yes. It complements, not replaces, good nutrition, regular movement, restorative sleep, and recovery time. Consult a qualified healthcare professional before starting any new supplement.
*These statements have not been evaluated by the FDA. ThymoQuin is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting a new supplement.